Inside the research
Cencora, Inc.
COR Research profile · latest available data
Price overview
$306.92
▼ -2.95 (-1.0%)
| 52w hi | $372.53 |
|---|---|
| 52w lo | $251.67 |
| Vol | 1.04M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.18
| Short | +0.10 |
|---|---|
| Medium | +0.28 |
| Long | +0.15 |
computed 2026-09-27
Key fundamentals
Cencora, Inc.
Healthcare · Medical Distribution
| Market cap | $58.57B |
|---|---|
| Enterprise value | $70.40B |
| Trailing P/E | 22.79x |
| Forward P/E | 15.48x |
| EV / EBITDA | 12.69x |
| P / S (ttm) | 0.18x |
| Profit margin | 0.8% |
| Return on equity | 96.9% |
| Revenue growth | +5.1% |
| Earnings growth | +11.9% |
| Debt / equity | 446.52 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.18 | |
| Sector | +0.08 | |
| Technical | +0.09 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Risk Metrics
| Beta vs SPX | -0.03 |
|---|---|
| Corr SPX | -0.02 |
| Annual vol | 26.7% |
| Annual ret | +18.5% |
| Sharpe | 0.69 |
| Max DD | -32.6% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $365.17 |
|---|---|
| High / Low | $429.00 / $280.00 |
| Median | $361.50 |
| Analysts | 12 |
| Strong Buy | 4 | |
|---|---|---|
| Buy | 8 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-07 | UBS | → Buy |
| 2026-05-07 | Evercore ISI Group | → Outperform |
| 2026-05-07 | Citigroup | → Buy |
| 2026-05-07 | Baird | → Outperform |
| 2026-04-28 | William Blair | → Market Perform |
| 2026-04-08 | Evercore ISI Group | → Outperform |
Officers & Board
| Director | Lorence Kim since 2022 |
|---|---|
| Director | Dennis M. Nally since 2020 |
| Director | Mark Durcan since 2015 |
| Director | Ornella Barra since 2015 |
| Director | Lon R. Greenberg since 2013 |
| CEO | Steven H. Collis since 2011 |
| Director | Steven H. Collis since 2011 |
| Director | Kathleen W. Hyle since 2010 |
| Director | Richard W. Gochnauer since 2008 |
| Director | Michael J. Long since 2006 |
| Director | Henry W. McGee since 2004 |
| Director | Jane E. Henney since 2002 |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-14 | Officer / Director Change | read |
| 2026-08-12 | Reg FD Disclosure | read |
| 2026-08-05 | Earnings Release, Reg FD Disclosure… | read |
| 2026-08-05 | Material Agreement, Material Obligation… | read |
| 2026-06-15 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-05-29 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-05-06 | Earnings Release, Reg FD Disclosure… | read |
| 2026-03-23 | Reg FD Disclosure, Exhibits | read |
| 2026-03-17 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-03-06 | Shareholder Vote | read |
| 2026-02-18 | Reg FD Disclosure, Other Material Event… | read |
| 2026-02-13 | Material Agreement, Material Obligation… | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-31 | NALLY DENNIS M | Grant | 113 | $35.18K | |
| 2026-07-31 | Cooper Ellen | Grant | 97 | $30.20K | |
| 2026-07-31 | Tyler Lauren M | Grant | 97 | $30.20K | |
| 2026-06-30 | Battaglia Silvana | Executive Vice President | Grant | 58 | $14.00K |
| 2026-06-30 | Campbell Elizabeth S | Executive Vice President | Grant | 50 | $12.00K |
| 2026-06-22 | Tyler Lauren M | Buy | 550 | $148.63K | |
| 2026-06-18 | DURCAN DERMOT MARK | Buy | 4.00K | $1.10M | |
| 2026-05-28 | DURCAN DERMOT MARK | Buy | 4.00K | $1.07M | |
| 2026-05-01 | Tyler Lauren M | Grant | 99 | $30.10K |
Flow & Concentration
| Insider 180d net | $2.31M |
|---|---|
| Insider buys / sells | 3 / 0 |
| Insider bias | Buyers |
| 13F holders | 9 |
| Top-5 share | 98.0% |
| HHI | 3,694 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $2.62B | 9.27M |
| Fidelity / FMR LLC | $1.17B | 4.12M |
| Citadel Advisors | $467.72M | 1.65M |
| Millennium Management | $278.02M | 982.48K |
| Capital Research / Capital World | $189.53M | 669.75K |
| AQR Capital Management | $76.38M | 272.73K |
| Bridgewater Associates | $9.63M | 34.05K |
| Renaissance Technologies | $6.68M | 23.62K |
| T. Rowe Price Group | $2.02M | 7.13M |
As of 2026-06-30
Dividends
| Yield (TTM) | 0.39% |
|---|---|
| $ / share (TTM) | $1.20 |
| 5y CAGR | -19.3% |
Annual dividend per share
| 2021 | $6.82 |
|---|---|
| 2022 | $1.87 |
| 2023 | $1.97 |
| 2024 | $2.08 |
| 2025 | $2.25 |
| 2026 | $0.60 |
Federal Contracts
| Amount | Agency | Description |
|---|---|---|
| $22.05K | Department of Veterans Affairs | PHARMACY ORDER WELIREG 40MG |
| $18.13K | Department of Veterans Affairs | PHARMACY ORDER BALVERSA 4MG TABS |
| $18.13K | Department of Veterans Affairs | PHARMACY ORDER BALVERSA 4MG TABLETS |
| $17.64K | Department of Veterans Affairs | PHARMACY ORDER BALVERSA 4MG TABS |
| $17.64K | Department of Veterans Affairs | PHARMACY ORDER BALVERSA 4MG TABS |
| $11.81K | Department of Veterans Affairs | PHARMACY ORDER BALVERSA 5MG TABLETS |
| $11.81K | Department of Veterans Affairs | PHARMACY ORDER BALVERSA 5MG TABLETS |
| $11.25K | Department of Veterans Affairs | PHARMACY ORDER BALVERSA 5MG TABLETS |
SEC Filings
The Long Run
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $321.33B | +10.0% | |
| Gross profit | $8.96B | +9.1% | |
| Operating income | $2.63B | +7.1% | |
| Net income | $1.55B | +8.9% | |
| Cash from ops | $3.88B | +10.5% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $308.95 | $310.89 | $304.31 | $306.92 | 1.04M |
| Sep 24 | $313.32 | $316.61 | $309.18 | $309.87 | 1.08M |
| Sep 23 | $315.51 | $320.24 | $310.71 | $312.28 | 1.10M |
| Sep 22 | $317.62 | $320.00 | $313.89 | $314.43 | 775.70K |
| Sep 21 | $309.74 | $316.98 | $308.51 | $316.49 | 1.05M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →